Inventor · disambiguated record
Jason K. Perry
Also filed as: PERRY JASON K
10 granted patents·5 pending applications·197 citations·filing 2007–2024
88Inventor score
Top patents by PatentIndex Score
15 records- 0196US7842672B2Phosphonate inhibitors of HCVGILEAD SCIENCES INC·Filed 2007·Granted Nov 30, 2010·103 cites·107 claims
- 0294US11224600B2Compounds for inhibition of alpha 4 beta 7 integrinGILEAD SCIENCES INC·Filed 2019·Granted Jan 18, 2022·9 cites·21 claims
- 0394US8324179B2Nucleoside analogs for antiviral treatmentCHEN JAMES M·Filed 2008·Granted Dec 4, 2012·72 cites·22 claims
- 0492US12091420B2SARS-COV2 main protease inhibitorsGILEAD SCIENCES INC·Filed 2023·Granted Sep 17, 2024·3 cites·28 claims
- 0590US12410183B2Sars-cov2 main protease inhibitorsGILEAD SCIENCES INC·Filed 2024·Granted Sep 9, 2025·1 cites·25 claims
- 0689US11179383B2Compounds for inhibition of α4β7 integrinGILEAD SCIENCES INC·Filed 2019·Granted Nov 23, 2021·3 cites·20 claims
- 0783US11174256B2Imidazopyridine derivativesGILEAD SCIENCES INC·Filed 2019·Granted Nov 16, 2021·2 cites·18 claims
- 0883US11116760B2Quinoline derivativesGILEAD SCIENCES INC·Filed 2019·Granted Sep 14, 2021·3 cites·23 claims
- 0979US11578069B2Compounds for inhibition of α4 β7 integrinGILEAD SCIENCES INC·Filed 2020·Granted Feb 14, 2023·1 cites·11 claims
- 1077US2025032473A1Quinoline derivativesGILEAD SCIENCES INC·Filed 2024·Application pending·0 cites
- 1175US2024239807A1Sars-cov2 main protease inhibitorsGILEAD SCIENCES INC·Filed 2023·Application pending·0 cites
- 1268US12053462B2Quinoline derivativesGILEAD SCIENCES INC·Filed 2021·Granted Aug 6, 2024·0 cites·18 claims
- 1365US2022226337A1Compounds for inhibition of alpha 4 beta 7 integrinGILEAD SCIENCES INC·Filed 2021·Application pending·0 cites
- 1465US2022152014A1Compounds for inhibition of alpha 4 beta 7 integrinGILEAD SCIENCES INC·Filed 2021·Application pending·0 cites
- 1563US2022135561A1Imidazopyridine derivativesGILEAD SCIENCES INC·Filed 2021·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →